In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

A bill filed in Springfield would allow doctors to prescribe some HIV medication without needing prior authorization.

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Ministry of Health Flags Off Critical Human Immunodeficiency Virus (HIV) Commodities at Mission for Essential Drugs and Supplies (MEDS) ...

Dolutegravir is one of the most effective and safest HIV medicines and is used by millions of adults and adolescents living ...